Sutro Biopharma Stock Analysis

Sutro Stock Analysis Notes

About 75.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.19. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sutro Biopharma has Price/Earnings To Growth (PEG) ratio of 0.12. The entity recorded a loss per share of 1.51. The firm had not issued any dividends in recent years. Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Sutro Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. To find out more about Sutro Biopharma contact William JD at 650 881 6500 or learn more at https://www.sutrobio.com.

Sutro Biopharma Investment Alerts

Sutro Biopharma Upcoming and Recent Events

Sutro Largest EPS Surprises

View All Earnings Estimates

Sutro Stock Institutional Investors

Note, although Sutro Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Sutro Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 136.06 M.

Sutro Profitablity

The company has Profit Margin (PM) of (0.77) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.97) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.97.

Management Efficiency

Sutro Biopharma has return on total asset (ROA) of (0.184) % which means that it has lost $0.184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1089) %, meaning that it created substantial loss on money invested by shareholders. Sutro Biopharma's management efficiency ratios could be used to measure how well Sutro Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of February 2025, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.22. At this time, Sutro Biopharma's Total Current Assets are very stable compared to the past year. As of the 27th of February 2025, Debt To Assets is likely to grow to 0.13, while Total Assets are likely to drop about 289.1 M.

Technical Drivers

As of the 27th of February, Sutro Biopharma has the Risk Adjusted Performance of (0.10), variance of 20.66, and Coefficient Of Variation of (673.42). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sutro Biopharma, as well as the relationship between them.

Sutro Biopharma Price Movement Analysis

Sutro Biopharma Insider Trading Activities

Sutro Biopharma Outstanding Bonds

Sutro Biopharma Predictive Daily Indicators

Sutro Biopharma Forecast Models

Sutro Biopharma's time-series forecasting models are one of many Sutro Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sutro Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Sutro Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sutro shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Sutro Biopharma. By using and applying Sutro Stock analysis, traders can create a robust methodology for identifying Sutro entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Sutro analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Sutro analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Sutro Biopharma stock analysis indicators help investors evaluate how Sutro Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Sutro Biopharma shares will generate the highest return on investment. By understating and applying Sutro Biopharma stock analysis, traders can identify Sutro Biopharma position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.